Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Direct recognition of hepatocyte-expressed MHC class I alloantigens is required for tolerance induction
Moumita Paul-Heng, Mario Leong, Eithne Cunningham, Daniel L. J. Bunker, Katherine Bremner, Zane Wang, Chuanmin Wang, Szun Szun Tay, Claire McGuffog, Grant J. Logan, Ian E. Alexander, Min Hu, Stephen I. Alexander, Tim D. Sparwasser, Patrick Bertolino, David G. Bowen, G. Alex Bishop, Alexandra Sharland
Moumita Paul-Heng, Mario Leong, Eithne Cunningham, Daniel L. J. Bunker, Katherine Bremner, Zane Wang, Chuanmin Wang, Szun Szun Tay, Claire McGuffog, Grant J. Logan, Ian E. Alexander, Min Hu, Stephen I. Alexander, Tim D. Sparwasser, Patrick Bertolino, David G. Bowen, G. Alex Bishop, Alexandra Sharland
View: Text | PDF
Research Article Hepatology Transplantation

Direct recognition of hepatocyte-expressed MHC class I alloantigens is required for tolerance induction

  • Text
  • PDF
Abstract

Adeno-associated viral vector–mediated (AAV-mediated) expression of allogeneic major histocompatibility complex class I (MHC class I) in recipient liver induces donor-specific tolerance in mouse skin transplant models in which a class I allele (H-2Kb or H-2Kd) is mismatched between donor and recipient. Tolerance can be induced in mice primed by prior rejection of a donor-strain skin graft, as well as in naive recipients. Allogeneic MHC class I may be recognized by recipient T cells as an intact molecule (direct recognition) or may be processed and presented as an allogeneic peptide in the context of self-MHC (indirect recognition). The relative contributions of direct and indirect allorecognition to tolerance induction in this setting are unknown. Using hepatocyte-specific AAV vectors encoding WT allogeneic MHC class I molecules, or class I molecules containing a point mutation (D227K) that impedes direct recognition of intact allogeneic MHC class I by CD8+ T cells without hampering the presentation of processed peptides derived from allogeneic MHC class I, we show here that tolerance induction depends upon recognition of intact MHC class I. Indirect recognition alone yielded a modest prolongation of subsequent skin graft survival, attributable to the generation of CD4+ Tregs, but it was not sufficient to induce tolerance.

Authors

Moumita Paul-Heng, Mario Leong, Eithne Cunningham, Daniel L. J. Bunker, Katherine Bremner, Zane Wang, Chuanmin Wang, Szun Szun Tay, Claire McGuffog, Grant J. Logan, Ian E. Alexander, Min Hu, Stephen I. Alexander, Tim D. Sparwasser, Patrick Bertolino, David G. Bowen, G. Alex Bishop, Alexandra Sharland

×

Figure 8

A monoclonal antibody against FR4 reduces Treg numbers in peripheral blood and spleen.

Options: View larger image (or click on image) Download as PowerPoint
A monoclonal antibody against FR4 reduces Treg numbers in peripheral blo...
Administration of the anti-FR4 monoclonal antibody TH6 (100 μg), i.v., was used to deplete the population of CD4+ Tregs from B10.BR mice. The nondepleting anti-FR4 antibody 12A5 does not compete for epitope binding against TH6 (Supplemental Figure 6) and was used for FR4 detection. TH6 treatment significantly reduced the numbers of both CD4+FoxP3+ T cells (gated on CD3+) and of the CD25+FR4+ fraction (gated on CD4+FoxP3+) in the peripheral blood (A and C) and spleen (B and D) of B10.BR mice at 24 hours after injection. CD4+FoxP3+ T cells in peripheral blood declined substantially from 6.98 × 104 ± 9.72 × 103 in controls to 1.09 × 104 ± 5.38 × 103 in TH6-treated mice (C) (P = 0.008), while a lesser reduction in CD4+FoxP3+ T cells (from 1.03 × 106 ± 2.19 × 104 to 7.86 × 105 ± 5.17 × 104, P = 0.01) was detected in the spleen (D). CD25+FR4+ T cells in peripheral blood decreased from 3.45 × 104 ± 5.59 × 103 to 216 ± 131(P = 0.0036) following anti-FR4 administration (C), whereas in spleen, the reduction in CD25+FR4+ T cells was from 3.86 × 105 ± 7.75 × 103 to 3.42 × 104 ± 3.02 × 103, P < 0.0001. While decline of the FR4+ fraction in spleen was accompanied by an overall reduction in CD4+FoxP3+ T cell numbers, there was also an increase in the proportion of CD25+FR4- cells upon TH6 treatment (B), suggesting that FR4 engagement may have resulted in shedding or internalization of this receptor on some cells. n = 3/group for all experiments. A and B show representative flow plots. In C and D, box shows minimum to maximum with a line at the mean. Data are described as mean ± SEM, and statistical analyses were performed using an unpaired t tests.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts